ReviewPlant cell reports2019
Genetic modification in Malaysia and India: current regulatory framework and the special case of non-transformative RNAi in agriculture.
Review in Plant cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Contact Unmodified Antisense DNA Biotechnology (CUADb)-Based Oligonucleotide Insecticides and RNA Biocontrols: Molecular Bases and Potential in Plant Protection.Current issues in molecular biology · 2026Review
- Building public trust and acceptance towards spray-on RNAi biopesticides: lessons from current ethical, legal and social discourses.GM crops & food · 2025Review
- Turning Susceptibility into Strength: A New Era of Durable Resistance in Plants Through Genome Editing.Plants (Basel, Switzerland) · 2025Review
- Genome editing in maize and sorghum: A comprehensive review of CRISPR/Cas9 and emerging technologies.The plant genome · 2025Review
- The future of dsRNA-based biopesticides will require global regulatory cohesion.Nature plants · 2025Article
- Review
- RNA Structure: Past, Future, and Gene Therapy Applications.International journal of molecular sciences · 2024Review
- Size variations of mesoporous silica nanoparticle control uptake efficiency and delivery of AC2-derived dsRNA for protection against tomato leaf curl New Delhi virus.Plant cell reports · 2023Article
- Recent Progress on Nanocarriers for Topical-Mediated RNAi Strategies for Crop Protection-A Review.Molecules (Basel, Switzerland) · 2023Review
- Is Malaysia Ready for Human Gene Editing: A Regulatory, Biosafety and Biosecurity Perspective.Frontiers in bioengineering and biotechnology · 2021Review
- Negligible transcriptome and metabolome alterations in RNAi insecticidal maize against Monolepta hieroglyphica.Plant cell reports · 2020Article
- Problem Formulation for Off-Target Effects of Externally Applied Double-Stranded RNA-Based Products for Pest Control.Frontiers in plant science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Recent developments in modern biotechnology such as the use of RNA interference (RNAi) have broadened the scope of crop genetic modification. RNAi strategies have led to significant achievements in crop protection against biotic and abiotic stresses, modification of plant traits, and yield improvement. As RNAi-derived varieties of crops become more useful in the field, it is important to examine the capacity of current regulatory systems to deal with such varieties, and to determine if changes are needed to improve the existing frameworks. We review the biosafety frameworks from the perspective of developing countries that are increasingly involved in modern biotechnology research, including RNAi applications, and make some recommendations. Malaysia and India have approved laws regulating living modified organisms and products thereof, highlighting that the use of any genetically modified step requires regulatory scrutiny. In view of production methods for exogenously applied double-stranded RNAs and potential risks from the resulting double-stranded RNA-based products, we argue that a process-based system may be inappropriate for the non-transformative RNAi technology. We here propose that the current legislation needs rewording to take account of the non-transgenic RNAi technology, and discuss the best alternative for regulatory systems in India and Malaysia in comparison with the existing frameworks in other countries.
Indexed as
Identifiers
31350570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.